147
Participants
Start Date
February 28, 2007
Primary Completion Date
October 31, 2008
Study Completion Date
November 30, 2008
Ganaxolone
Oral suspension 200-500 mg 3x/day
Placebo
non-active placebo
Neurosciences Institute at Albany Medical Center, Albany
SUNY Upstate Medical University, Syracuse
Riddle Health Care Center for Neuroscience, Media
Drexel University / Hahneman Hospital, Philadelphia
Thomas Jefferson University, Philadelphia
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Virginia Commonwealth University, Richmond
Emory HealthCare, Atlanta
Intercoastal Medicine, Sarasota
Vanderbilt University Medical Ctr, Nashville
University of Kentucky, Dept. of Neurology, Lexington
Ohio State University Medical Center, Columbus
2799 West Grand blvd. CFP 071, Detroit
University of Iowa Hospitals and Clinics, Iowa City
Southern Illinois University Medical Center, Springfield
Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield
Arkansas Epilepsy Program, Little Rock
Neurological Clinic of Texas, P.A., Dallas
Barrow Neurological Institute, Phoenix
University of Southern California Adult Comprehensive Epilepsy Center, Los Angeles
University of California-Davis, Sacramento
University of Alabama, Birmingham
Anchutz Outpatient Pavillion Neurosciences Clinic/ University of Colorado Hospital, Aurora
Yale University School of Medicine, New Haven
University of Florida McKnight Brain Institute, Gainesville
Minnesota Epilepsy Group, PA, Saint Paul
Overlook Hospital and Hackensack Medical Center, Hackensack
Lead Sponsor
Marinus Pharmaceuticals
INDUSTRY